MetMAb

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Non-Small Cell Lung CancerSolid Cancers

Phase 1

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

CompletedNCT01068977

Genentech, Inc.Solid Cancers

Start: 2007-08-31End: 2010-01-31Updated: 2017-05-19

Phase 2

A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

CompletedNCT00854308

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2009-04-30End: 2012-01-31Updated: 2017-03-31